INTRODUCTION
Hepatocellular carcinoma (HCC) is one of the leading causes of death worldwide. D e s p i t e t h e r ap e u t i c a n d diagnostic advances, HCC has a poor prognosis. The majority of HCCs develop in the context of chronic hepatitis, particularly in cirrhotic patients, with an annual incidence of 2-8% [1] .
According to the 2017 World Health Organization (WHO) Global Hepatitis Report, around 71 million persons are estimated to be affected by chronic hepatitis C and, in the year 2015, there were more new infections than treatments [2] . Overall, the prevalence of chronic hepatitis C seems to be decreasing while the liver-related mortality from hepatitis C virus (HCV) infection is expected to increase [3] [4] [5] . HCV eradication, which is deemed feasible in about 15-20 years, is the main road to a global reduction of mortality from HCV related liver disease and hence from HCC.
However, the elimination of HCV infection reduces the risk of developing HCC but does not eliminate it. As observed both ORIGINAL PAPER J Gastrointestin Liver Dis, December 2019 Vol. 28 No 4: [449] [450] [451] [452] [453] [454] [455] [456] in the interferon and in the direct-acting antiviral (DAA) era, cirrhotic patients remain at risk of developing HCC even after the sustained virologic response (SVR) [6] [7] [8] [9] [10] .
The identification of HCV patients achieving SVR who remain at risk of developing HCC is now the primary goal, necessary to tailor the follow-up after eradication. Clinical studies have identified several risk factors for HCC development among which male gender, obesity, non-alcoholic fatty liver disease (NAFLD), cirrhosis, alcohol abuse and smoking [1] . More recently, genetic studies have focused on predisposing genetic factors, such as single nucleotide polymorphisms (SNPs), that may impact the pathway to HCC development [11, 12] Patatin-like phospholipase domain containing 3 (PNPLA3) is a gene coding for a phospholipase, also known as adiponutrin, involved in the triglyceride and retinol ester metabolism. The rs738409 variant (C>G p.I148M) has been associated with a higher risk of steatosis, cirrhosis and HCC development, independently from other risk factors [13] [14] [15] [16] [17] [18] [19] . This variant has been associated with reduced serum levels of retinol and retinol-binding protein 4 (RBP4) [20] [21] [22] [23] [24] .
Transmembrane 6 superfamily member 2 (TM6SF2) and membrane-bound O-acyltransferase domain-containing protein 7 (MBOAT7) variants, namely genotype rs641738, have been proposed as genetic factors favoring disease progression from steatosis to NASH and cirrhosis in European descent [25] .
Interleukin-28B (IL28B) is part of the interferon lambda family, which is essential for the immune response to viruses. In the past, the variant rs12979860 (coding for the T allele) has been associated with an inadequate response to interferon/ ribavirin based therapies while in the DAA era this variant did not seem to impact SVR [26-28]. However, even though with variable results, the IL28B polymorphisms have been associated with different propensities to fibrosis evolution [29] . A recent meta-analysis has suggested that the T-allele of rs12979860 significantly increases the risk of HCC in Caucasians [30] .
The Tissue inhibitor of metalloproteinases 1 and 2 (TIMP-1 and TIMP-2) are two genes encoding for matrix metalloproteinase (MMP) inhibitors that are extracellular endopeptidases primarily responsible for the degradation of extracellular matrix (ECM). By regulating the ECM environment, they have a role in fibrosis progression and facilitate tumor cells invasion and migration across the stroma for distant metastasis [31, 32] Nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kB) is a transcription factor involved in many processes among which it has a crucial role in the regulation of immune response and inflammation [33] . The SNP rs28362491, a variant in the promoter region, has been associated with progression to cirrhosis and may have a role in HCC development [34] .
Based on these premises, we aimed to evaluate whether the SNPs: PNPLA3 (rs738409), TM6SF2 (rs58542926), MBOAT7 (rs641738), IL28B (rs12979860), TIMP-1 (rs4898), TIMP-2 (rs8179090), NF-kB promoter (rs28362491) may represent predisposing factors for HCC development after HCV eradication with DAAs. Secondarily, we aimed to evaluate whether the PNPLA 3 variant I148M is associated with reduced retinol serum levels, which may constitute a risk factor for tumor development.
METHODS

Patients
All patients with chronic hepatitis C and advanced fibrosis (F3-F4) according to Liver Stiffness Measurement (LSM) >9.5 kilopascals (kPa) [35] who underwent DAAs therapy in our outpatient clinic of an academic hospital were consecutively enrolled starting from 2016. The entire population undergoing DAAs consisted of 344 patients, of whom 200 accepted to enter the study.
SNPs were evaluated in all patients in a single blood draw 24 weeks after the end of treatment (EOT). Besides standard routine laboratory testing for HCV, also serum retinol and retinol-binding protein 4 (RBP4) were evaluated. Patients were advised to avoid any dietary or vitamin supplement containing vitamin A or carotenoids in the three days before the blood draw. Similarly, they were asked to limit meat and egg as well as to avoid interfering food (i.e. tomatoes, carrots, persimmon, eel, liver and offal).
Inclusion criteria for the subsequent statistical analysis were: being treated with DAAs for HCV, older than 18 years and able to understand and sign the informed consent. Exclusion criteria were: unavoidable use of dietary and vitamin supplements, inability to follow the suggested diet in the three days before the blood draw, ethanol abuse, and a diagnosis of rare liver disease, liver transplantation, and bone marrow transplantation. All patients were followed according to the standard of care, and we had no patient lost on follow-up.
Surveillance and HCC assessment
Before starting antiviral treatment, all patients underwent abdomen ultrasound (US). If a suspicious focal lesion was detected in the liver, the diagnostic workup was completed with contrast-enhanced ultrasonography (CEUS) and subsequent computer tomography (CT) scan or magnetic resonance imaging (MRI) to exclude the presence of HCC. All patients with a history of HCC underwent CT scan or MRI, besides US, to exclude recurrent HCC before starting treatment. In all patients with a history of HCC, the minimum period between the last treatment for HCC and DAAs treatment was at least six months.
All patients were followed up for at least six months after EOT or until HCC development. During the follow-up period, the patients had repeated US evaluation as recommended by the surveillance program guidelines [1] ; in case of suspicion of HCC development, CEUS/CT/MRI were carried out to confirm or exclude the presence of HCC.
DNA analysis
The following SNPs were studied: PNPLA3 (rs738409), TM6SF2 (rs58542926), MBOAT7 (rs641738), IL28B (rs12979860), TIMP-1 (rs4898), TIMP-2 (rs8179090), and NF-kB promoter (rs28362491).
Whole blood was used to extract DNA for SNP evaluation. Samples were frozen to -20°C until use. An aliquot of 400 µL was processed with the semi-automatic instrument J Gastrointestin Liver Dis, December 2019 Vol. 28 No 4: 449-456 Maxwell® 16 (Promega Corporation, Madison, WI USA), able to purify DNA from 16 samples simultaneously. DNA was purified with a specific kit (Maxwell 16 DNA Purification Kits, Promega Corporation, Madison, WI USA) and then quantified with the spectrophotometer Nanodrop 3.0.0. " (Celbio S.P.A, Milano, Italia). SNPs genotyping was performed in a 384 well-plate format on the Sequenom MassARRAY iPLEX platform (Sequenom, San Diego, USA). Primers were designed using the dedicated online software Assay Design v.4.0 (http://www.mysequenom.com, Sequenom Inc., San Diego, CA, USA). After the polymerase chain reaction, analytes were transferred from the plate to the microchip (SpectroCHIP bioarray®) using the MassARRAY Nanodispenser (Samsung). The loaded microchip was then put into the mass-spectrometer (MALDI-TOF; Matrix-Assisted Laser Desorption/Ionisation Time Of Flight; Sequenom Inc., San Diego, CA, USA) for analysis. Data acquisition occurred through dedicated software.
Ethics
The study was conducted following the Declaration of Helsinki (revision of Edinburgh, 2000) and was approved by our institutional Ethical Committee (approval number 118/2016/U/Tess; amendment EM298/2017/U). All subjects signed written informed consent.
Statistical analysis
Categorical data were expressed as numbers (percentages) and continuous variables as medians (IQR or range). For group comparison, the Mann-Whitney U test was used for continuous variables and the chi-square test for categorical variables. Spearman rank correlations were calculated to measure and to test the association between SNPs and HCC development. Univariate and multivariate logistic regression analysis was performed to determine predictors of HCC development. Multivariable logistic regression analyses were conducted on variables (sex, ALT, IL28B rs12979860, Retinol, RBP) that reached p<0.2 at univariate analysis. Model discrimination was assessed calculating the Area under the Receiver Operator Characteristic (ROC) curve, whereas model calibration has been determined by the Hosmer-Lemeshow (H-L) chi-square test. P-values less than 0.05 were considered statistically significant. The statistical analysis was conducted using Stata/ SE (Version 14.2; Stata Corp, Texas, U.S.A.).
RESULTS
The demographic and clinical characteristics of the population under study are reported in Table I .
Almost all patients (197/200) obtained SVR at 24 months. Seventeen patients (8.8%) were treated for HCC before DAAs treatment (10 surgery, 9 TACE/PEI, 4 RFA) and 6 of them (3% overall; 35.29% of previously treated HCC) developed a recurrence (previous treatment: 4 surgery, 1 PEI, 1 RFA) after a mean period of 18 months from EOT. Five (2.5%) patients without a history of liver malignancy developed HCC after DAAs therapy after a mean period of 18 months after EOT. All patients who developed HCC had obtained SVR24 and none of these showed HCV re-infection.
Analyzing distribution of the genetic risk factors under study, a significant difference was found for IL28 between patients without HCC and those with recurrence or de novo HCC after DAAs; MBOAT7 resulted significant only in the subgroup of patients with HCC recurrence and without history of HCC while TIMP1 was significant only in patients with HCC recurrence (Table II) . However, when we analyzed the correlation between the studied SNPs and HCC we found no significant association (Table III) 
DISCUSSION
Recent literature data debate the initial reports of increased frequency of de novo HCC development following antiviral treatment with DAAs for HCV infection [9, 36] . New studies reported no significant increase in recurrence and a decreased incidence of de novo HCC development after SVR in cirrhotic patients treated with DAA [7, [37] [38] [39] . Recently, a comprehensive cohort study found an incidence of HCC following DAAs treatment for HCV of 1.82% with a 76% reduction in the risk of tumor development in patients with SVR [7]. Furthermore, the authors found no significant difference in tumor biology between early and delayed HCC nor any significant factor differentiating patients who developed the tumor during treatment or later during follow-up [7] . This study suggested that SVR reduced the risk of HCC development, but that the risk is not zero. Similar results have also been published in two extensive cohort studies [40, 41] .
These findings are in line with the data obtained with the interferon/peg interferon-based treatments, when SVR was associated with a significant reduction in the risk of HCC development, but the risk was not eliminated [42] [43] [44] . Nowadays we are treating with DAAs more severe patients compared to those treated with interferon/peginterferon. Therefore, given the fact that a small subset of cirrhotic patients achieving SVR will still develop HCC, it is essential to identify the patients at risk that may benefit from a closer follow-up. On the other hand, identifying patients at low or no risk may save financial resources by tailoring monitoring and follow-up.
In the present study, we aimed to identify SNPs that may constitute a risk factor for HCC development after DAAs treatment. We selected 7 SNPs dealing with immune response, metabolic factors, extracellular matrix and inflammatory pathways that have been suggested to be related to tumor development. Secondarily, we evaluated serum retinol levels that have been related to tumor development of different kinds [22, 23, [45] [46] [47] and with the PNPLA3 variant I148M [21, 24] . J Gastrointestin Liver Dis, December 2019 Vol. 28 No 4: 449-456 Surprisingly, we did not find any significant association between the majority of the selected SNPs and HCC development, nor between serum retinol levels and PNPLA3 variant I148M. However, this latter result may have been biased by the fact that the majority of patients had advanced fibrosis, and in this case, serum retinol may not reflect liver storage [48] .
Only IL28B TT was significantly associated with HCC development after DAAs treatment. IL28B genotype has long been evaluated as a factor conditioning response to interferonbased treatments, with genotype CC associated with more favorable results in terms of SVR [28, 49, 50] . When DAAs became available, this genotype was no longer a limiting factor since the potency of the new drugs overcame this factor of non-response [51] . IL-28 or interferon lambda is a type III interferon, an essential immune mediator that has been shown to have both antiviral as well as anti-tumor activity [52] [53] [54] . The precise mechanisms underlying these properties are still not completely unraveled. Concerning HCV, it has been demonstrated that IL28 interferes with both entry [55] and replication [56] [57] of the virus into the cell supporting its impact in HCV clearance, mainly in genotype 1, in the era of PEGylated interferons [49] . The high potency of DAAs with SVRs above 90% suggested that even not optimal individual immune responses can be overcome by these drugs, making IL28B genotyping not necessary. The antitumor activity is thought to imply the same mechanisms elucidated for type I interferons, inducing cell apoptosis and cell cycle arrest [52] . It has been previously shown that the IL28B CT/TT polymorphisms were associated with progression to cirrhosis and HCC in viral hepatitis C suggesting that the presence of these alleles represent a risk factor for HCC development coupled to cirrhosis per se [58] . It is therefore tempting to speculate that in cirrhotic individuals carrying the unfavorable IL28 genotypes this higher susceptibility to tumor development might be maintained after viral eradication because of a less effective immune response.
IL28B codes for a member of the interferon lambda family, these molecules have essential functions in several biological events. They degrade viral genetic material and block viral replication showing antiviral effects [59, 60] . Beside the antiviral properties, interferon lambda shows other antitumor activities such as cell cycle arrest, apoptosis induction, enhancement of Natural Killer activity and up-regulation of major histocompatibility complex, class I (MHC-I) [59, 60] . It seems logical that a less active TT genotype determining a less effective innate antiviral response as well as a defective anti-tumor activity may constitute a significant risk factor for HCC development in cirrhotic patients despite achieving SVR. An Italian study evaluated the association between the rs12979860 IL28B polymorphism and HCC development in chronic hepatitis C patients enrolled in the years 1989 -1992 and followed up for a mean of 14.8 years [61] . The authors did not find any association; however, of the originally enrolled patients (465), only 264 accounted for the final results undermining the reliability of the results. Furthermore, patients were enrolled and treated in the pre-DAAs era [61] .
A previous Asian study evaluating the IL28B rs12979860 polymorphism in a vast population with HCV treated with PEGylated interferon plus ribavirin reported an association with HCC development in patients without SVR [62] . However, response rates with PEGylated interferon plus ribavirin are slightly different from those obtained with DAAs and a significant proportion of patients (the more severe) who would now obtain an SVR are left out. Looking at the whole population, the hazard ratio of 1.59 (95%CI 1.01-2.51, p=0.046) at multivariate analysis is reported for the association with HCC development after treatment [63] . A recent metaanalysis evaluating the association of the IL28B rs12979860 polymorphism with HCC independently from treatment or etiology found that this association is stronger in Caucasians than in Asians [30] . Therefore, we think that the results of the study conducted by Chang et al. [30] are comparable to ours.
Obviously, HCC development is a biological process that encompasses several different settings, and other SNPs are expected to associate with tumor development after SVR with DAAs. To our knowledge, at least other two SNPs, TLL1 and MICA, have been reported to be associated with HCC after SVR [64, 65] . Therefore, the combined evaluation of different SNPs may further enhance our capability of identifying patients at risk of developing HCC despite SVR.
We should also not forget the other known risk factors predicting an increased probability of HCC development, such as older age, lower platelet count, high α-fetoprotein (AFP) levels, non-improvement of liver fibrosis/liver stiffness, HBV, smoking, and coexistence of nonalcoholic steatohepatitis [66] [67] .
The present study suffers because of a relatively low number of patients with HCC post DAA treatment and a mean followup period below two years that may have limited the number of cases and subgroup analyses. However, the population was well studied and characterized and an increase in the number of cases is unlikely to change the obtained results.
CONCLUSION
We found a significant association of the IL28B rs12979860 polymorphism with HCC development after SVR obtained J Gastrointestin Liver Dis, December 2019 Vol. 28 No 4: 449-456 with DAAs, suggesting that assessment of this SNP is advisable to identify patients at risk of tumor development after treatment. An algorithm, including genetic background and the other variables associated with HCC development, may help the clinician to tailor a more stringent follow-up of patients at higher risk. Further prospective studies are required to confirm these hypotheses. 
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